Erlotinib

證據等級: L5

預測適應症: 10 個

Erlotinib: From Non-Small Cell Lung Cancer to Ewing Sarcoma

One-Sentence Summary

Erlotinib (Tarceva®) is a first-generation EGFR tyrosine kinase inhibitor originally approved for the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. The TxGNN model predicts it may be effective for Ewing Sarcoma, with 1 clinical trial and 2 publications currently supporting this direction. Evidence remains at the preclinical and mechanistic stage only, and the sole registered clinical trial was withdrawn before enrolling any patients.

Quick Overview

Item	Content
Original Indication	Non-small cell lung cancer (NSCLC) and pancreatic cancer
Predicted New Indication	Ewing Sarcoma
TxGNN Prediction Score	95.77%
Evidence Level	L4 (Preclinical / Mechanistic)
Australia Market Status	Not currently listed (no ARTG registration)
Number of ARTG Entries	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data was not available in the current evidence pack. Based on published literature included in this review, Erlotinib is a selective inhibitor of the EGFR (epidermal growth factor receptor) tyrosine kinase, blocking EGFR-mediated downstream signalling pathways — including RAS/MAPK and PI3K/AKT — that govern tumour cell proliferation, survival, angiogenesis, and resistance to apoptosis. It was the first EGFR-targeted agent approved for NSCLC in unselected patients, and remains a standard of care for EGFR-mutant NSCLC.

The mechanistic link to Ewing Sarcoma is biologically plausible: approximately 50% of Ewing Sarcoma tumours overexpress EGFR, and the disease-defining EWS-FLI1 fusion oncoprotein can indirectly activate EGFR downstream signalling (RAS/MAPK axis). A paediatric sarcoma xenograft study (PMID 29080385) specifically evaluated the combination of Erlotinib with the HER3-targeting antibody patritumab, demonstrating synergistic anti-tumour activity in Ewing Sarcoma models through simultaneous EGFR-HER3 heterodimer blockade.

However, a critical distinction must be noted: activating EGFR mutations — which are the key predictor of TKI response in NSCLC — are exceedingly rare in bone and soft tissue sarcomas, including Ewing Sarcoma. EGFR overexpression alone without a driving mutation substantially weakens the mechanistic rationale and means that NSCLC clinical evidence cannot be directly extrapolated. This classification mismatch is the primary reason this prediction remains at the research hypothesis stage.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrolment	Key Findings
NCT02689336	Phase 2	Withdrawn	0	Genomically-targeted Erlotinib + Temozolomide in relapsed/recurrent/refractory paediatric solid tumours harbouring EGFR, ERBB2, or JAK2 mutations; Ewing Sarcoma was among eligible tumour types. Trial was withdrawn before any patients were enrolled, producing no efficacy or safety data. This represents a negative feasibility signal — the underlying reason for withdrawal (recruitment difficulties, funding, or scientific concerns) requires further investigation.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
29080385	2018	Preclinical / Translational	Pediatric Blood & Cancer	Evaluated patritumab (HER3 antibody) alone or combined with Erlotinib alongside standard cytotoxics (cisplatin, vincristine, cyclophosphamide) in paediatric sarcoma xenograft models expressing EGFR/HER3. Demonstrated synergistic anti-tumour activity through dual EGFR-HER3 blockade in Ewing Sarcoma models — the most directly relevant study in this evidence pack.
26835334	2014	Review	Translational Pediatrics	Broad overview of advances in paediatric cancer treatment over 50 years, including risk-adapted therapeutic approaches and emerging targeted strategies in childhood cancers. Provides contextual background for novel agent evaluation in paediatric solid tumours.

Australia Market Information

Erlotinib is not currently registered on the Australian Register of Therapeutic Goods (ARTG). There are no approved products, no listed dosage forms, and no TGA-approved Product Information available through the ARTG. Any clinical use in Australia would require access via the Special Access Scheme (SAS) or a comparable regulatory pathway.

Cytotoxicity

Erlotinib is an anticancer agent (EGFR-targeted TKI) used for the treatment of malignant disease.

Item	Content
Cytotoxicity Classification	Targeted therapy — First-generation EGFR tyrosine kinase inhibitor (4-anilinoquinazoline class)
Myelosuppression Risk	Low (myelosuppression is uncommon with EGFR-TKIs; haematological toxicity is not a class-defining adverse effect)
Emetogenicity Classification	Low to minimal
Monitoring Items	Liver function tests (LFTs) at baseline and periodically; full blood count (FBC); renal function; pulmonary function / chest imaging if respiratory symptoms develop (interstitial lung disease); regular skin toxicity assessment (acneiform rash, paronychia, xerosis)
Handling Protection	Standard oral cytotoxic handling precautions apply; follow institutional cytotoxic drug handling and disposal policies

Safety Considerations

Please refer to the TGA-approved Product Information (PI) — or, given the absence of Australian registration, the equivalent international PI (e.g., FDA label for Tarceva®) — for comprehensive safety information.

Note: No safety data (key warnings, contraindications, or drug-drug interaction data) was retrievable in the current evidence pack. Before any clinical decision-making, safety information must be obtained from authoritative prescribing documentation. Of particular note: Erlotinib is associated with class-specific dermatological toxicity (acneiform rash, skin barrier disruption), interstitial lung disease, and hepatotoxicity. Given the proposed paediatric oncology context, age-appropriate dosing and safety data would also need to be confirmed.

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence for Erlotinib in Ewing Sarcoma is currently limited to a single preclinical xenograft study and one Phase 2 clinical trial that was withdrawn before any patients were enrolled — producing no human efficacy or safety data. While the EGFR overexpression-based mechanistic rationale is scientifically interesting, the absence of activating EGFR mutations in this tumour type substantially undermines the biological basis for single-agent EGFR-TKI activity.

To proceed to the next stage, the following is needed:

EGFR biomarker profiling: Determine EGFR overexpression rates and mutation status in representative Ewing Sarcoma patient cohorts to identify any potentially responsive subgroup
Withdrawal investigation: Clarify the reason for NCT02689336 withdrawal — recruitment failure would leave the scientific question open; safety signal or lack of efficacy would constitute a stronger case against progression
MOA and safety data: Obtain full Erlotinib Product Information (FDA/EMA label) to complete the safety assessment, including paediatric-specific dosing guidance
Combination strategy evaluation: Given the preclinical synergy data with patritumab (HER3 antibody), a combination hypothesis warrants formal preclinical programme development before any human studies
TGA regulatory pathway: If clinical investigation is pursued in Australia, a Named Patient Program (NPP) application or Special Access Scheme (SAS) Category B pathway would be required, given the absence of ARTG registration
Paediatric ethics and trial design: Any future clinical investigation would require paediatric-specific ethics review and trial design considerations given the primary patient population

This report is generated from the TxGNN drug repurposing research platform and is intended for research and healthcare professional review purposes only. Findings do not constitute medical advice and require clinical validation before any therapeutic application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.